- Home
- ACXP
as 05-15-2025 4:00pm EST
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STATEN ISLAND |
| Market Cap: | 8.4M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 142.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $3.33 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acurx Pharmaceuticals Inc. News
ACXP Breaking Stock News: Dive into ACXP Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
PR Newswire
16 days ago
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
PR Newswire
18 days ago
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
PR Newswire
a month ago
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
ACCESS Newswire
a month ago
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
ACCESS Newswire
a month ago
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming
ACCESS Newswire
a month ago
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman — as Sponsored Programming
ACCESS Newswire
a month ago
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming
Compare ACXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACXP Acurx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.